- Home
- USAU vs CRBP Comparison
USAU vs CRBP Comparison
Compare USAU & CRBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | USAU | CRBP |
|---|---|---|
| Founded | 2014 | 2009 |
| Country | United States | United States |
| Employees | N/A | 36 |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 214.2M | 190.3M |
| IPO Year | 2020 | 2014 |
Fundamental Metrics
Financial Performance| Metric | USAU | CRBP |
|---|---|---|
| Price | $16.44 | $10.39 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | $22.83 | ★ $45.50 |
| AVG Volume (30 Days) | 234.5K | ★ 343.4K |
| Earning Date | 03-16-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 36.11 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $17,402,000.00 | $4,822,272.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $116.00 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 97.62 |
| 52 Week Low | $11.91 | $7.12 |
| 52 Week High | $23.72 | $20.56 |
Technical Indicators
Market Signals| Indicator | USAU | CRBP |
|---|---|---|
| Relative Strength Index (RSI) | 65.57 | 59.38 |
| Support Level | $16.35 | $8.30 |
| Resistance Level | $18.06 | $10.74 |
| Average True Range (ATR) | 0.63 | 0.54 |
| MACD | 0.23 | 0.03 |
| Stochastic Oscillator | 78.50 | 68.27 |
Price Performance
Historical ComparisonAbout USAU U.S. Gold Corp.
U.S. Gold Corp is a gold, copper and precious metals development and exploration company pursuing exploration opportunities mainly in Wyoming, Nevada and Idaho. It is an exploration and development company that owns certain mining leases and other mineral rights comprising the CK Gold Project in Wyoming, the Keystone Project in Nevada and the Challis Gold Project in Idaho. The company is engaged in the exploration and evaluation of its mineral properties, which is the single operating segment.
About CRBP Corbus Pharmaceuticals Holdings Inc.
Corbus Pharmaceuticals Holdings Inc is a clinical stage company focused on new therapies in oncology and obesity and is committed to helping people defeat serious illness by bringing inventive scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.